Global CDMO founded in 1997 offering integrated biologics development and manufacturing services, spanning mammalian and microbial platforms from cell line development to commercial production.
KBI Biopharma, Inc. is a global contract development and manufacturing organization (CDMO) that provides fully integrated drug development and biomanufacturing services to life science companies. Founded in 1997 and headquartered in Durham, North Carolina, with additional global facilities, the company covers the full development path from early-stage work through clinical and commercial manufacturing. It is part of the JSR Life Sciences group.
Technical work spans mammalian biologics and microbial expression systems, including cell line development, process development, analytical development, formulation development and biologics characterization, alongside clinical and commercial biomanufacturing and vaccine development. Two proprietary platforms underpin much of this capability: the SUREtechnology Platform for mammalian systems and the PUREplatform microbial expression system.
The company has operated for nearly three decades and received top honors in the 2025 CDMO Leadership Awards. It describes its approach as combining deep scientific expertise with operational excellence, with a focus on accelerating timelines and simplifying the path from discovery to patient.
